Descriptors
Documents disponibles dans cette catégorie (117)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Extend search on down-posting(s)
[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium] / Christoph Schwierz / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium] : Part 2 [printed text] / Christoph Schwierz, Author ; Nancy Thiry, Author ; Stefaan Van de Sande , Author ; Mohamed Gamil, Author ; Frederik Nevens, Author ; Isabelle Colle, Author ; Yvres Horsmans, Author ; Frank Hulstaert, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011. - (KCE Reports. Health Technology Assessment (HTA); 157) .
Study n° 2008-11 HTA Chronic hep B
Languages : English (eng)
Descriptors: Indexation
2008-11 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis B virus ; Hepatitis B, Chronic ; R157
Classification
WC 536 Human viral hepatitisContents note: GLOSSARY 2 -- 1 BACKGROUND AND OBJECTIVES 3 -- 1.1 NATURAL HISTORY AND EPIDEMIOLOGY 3 -- 1.2 TREATMENT 4 -- 1.3 OBJECTIVES AND CONTENT OF THE TWO REPORTS 5 -- 2 METHODS 7 -- 2.1 TARGET POPULATION 7 -- 2.2 MODEL STRUCTURE AND BASIC ASSUMPTIONS 7 -- 2.3 TRANSITION PROBABILITIES 9 -- 2.4 DISEASE MANAGEMENT AND TREATMENT COSTS 12 -- 2.5 UTILITIES 13 -- 2.6 ANTIVIRAL TREATMENT 14 -- 3 RESULTS 16 -- 3.1 MODEL VALIDATION: NATURAL EVOLUTION OF DISEASE WITHIN EUROPEAN -- COHORTS 17 -- 3.2 HEALTH OUTCOMES 18 -- 3.2.1 Life-years gained in the three cohorts 18 -- 3.2.2 Undiscounted life-years gained in DC and HCC 19 -- 3.2.3 Mean tenofovir treatment duration in CHB e+ vs e- cohorts 20 -- 3.3 BASE-CASE COST-UTILITY ANALYSES 20 -- 3.3.1 Overview of the results for the three base-case cohorts 20 -- 3.3.2 CHBe+ non-cirrhotic Europeans 21 -- 3.3.3 CHBe- non-cirrhotic Europeans 23 -- 3.3.4 Patient with compensated liver cirrhosis 25 -- 3.4 SCENARIO AND PROBABILISTIC SENSITIVITY ANALYSES 27 -- 3.4.1 Probabilistic sensitivity analysis 27 -- 3.4.2 ICERs in function of the time horizon 30 -- 3.4.3 Asian cohorts 31 -- 3.4.4 Variations in the discount rates 32 -- 3.5 BUDGET IMPACT 33 -- 4 DISCUSSION AND CONCLUSIONS 34 -- 5 APPENDICES 37 -- 5.1 NATURAL PROGRESSION TO LIVER CIRRHOSIS IN 278 CHRONIC HEPATITIS B -- PATIENTS OF EUROPEAN ORIGIN, THE IMPORTANCE OF AGE AND ELEVATED ALT . 37 -- 5.1.1 Introduction 37 -- 5.1.2 Aim 37 -- 5.1.3 Methods 37 -- 5.1.4 Results 38 -- 5.1.5 Discussion and Conclusion 39 -- 5.2 COMPARISON OF PUBLISHED QUALITY OF LIFE DATA 40 -- 5.2.1 Aims 40 -- 5.2.2 Methods 41 -- 5.2.3 Results 43 -- 5.3 DISEASE MANAGEMENT COSTS 46 -- 5.3.1 Data sources 48 -- 5.3.2 Primary inclusion counts 52 -- 5.3.3 Exclusions and sub grouping for cost study 53 -- 5.3.4 Extrapolations for partial lump sum remunerations 59 -- 5.3.5 Results 66 -- 5.3.6 Discussion 72 -- 6 REFERENCES 74 Link for e-copy: https://kce.fgov.be/publication/report/economic-evaluation-of-antiviral-treatmen [...] Format of e-copy: Webpage Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2584 Copies(0)
Status No copy Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C [printed text] / Sophie Gerkens , Author ; Nancy Thiry, Author ; Frank Hulstaert, Author ; Jo Robays, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2016 . - 144 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 276C) .
ISSN : D/2016/10.273/88 : € 0,00
Study 2015-08
Languages : English (eng)
Descriptors: Indexation
2015-08 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis C ; R276
Classification
WC 536 Human viral hepatitisContents note: SCIENTIFIC REPORT 14 -- 1 INTRODUCTION .14 -- 1.1 BACKGROUND 14 -- 1.1.1 Transmission 14 -- 1.1.2 Hepatitis C in Belgium 15 -- 1.1.3 Treatments 16 -- 1.2 OBJECTIVE OF THIS REPORT AND RESEARCH QUESTIONS 17 -- 2 REVIEW OF THE PUBLISHED ECONOMIC EVALUATIONS 18 2.1 INTRODUCTION .18 -- 2.2 METHODS 18 2.2.1 Inclusion and exclusion criteria .18 -- 2.2.2 Search strategy .19 2.2.3 Selection procedure 19 2.2.4 Coverage of the reviews 21 -- 2.3 CLASSIFICATION OF THE ECONOMIC EVALUATIONS 21 -- 2.3.1 Early publications based on emerging and weak evidence 21 -- 2.3.2 Pegylated interferon as an intervention 21 -- 2.3.3 Disease progression after sustained viral response 22 -- 2.3.4 Selected economic evaluations 22 -- 2.4 OVERVIEW OF THE SELECTED ECONOMIC EVALUATIONS 23 -- 2.4.1 Country and study design 23 -- 2.4.2 Perspective .23 -- 2.4.3 Time horizon and discount rate .23 -- 2.4.4 Targeted patient group 23 -- 2.4.5 Intervention and comparators 23 -- 2.4.6 Assumptions used in modelling the HCV natural history .24 2.4.7 Non-liver mortality 25 -- 2.4.8 Quality of life 25 -- 2.5 MAIN RESULTS OF THE ECONOMIC EVALUATIONS 34 -- 2.5.1 Genotype 1 34 -- 2.5.2 Genotype 2 35 -- 2.5.3 Genotype 3 35 -- 2.5.4 Genotype 4 35 -- 2.6 SENSITIVITY AND SUBGROUP ANALYSES .35 -- 2.6.1 Sensitivity analyses .35 -- 2.6.2 Subgroup analyses .35 -- 2.7 DISCUSSION 41 -- 2.7.1 Summary of the results .41 -- 2.7.2 General conclusion .42 -- 3 THE COST-EFFECTIVENESS AND BUDGET IMPACT OF TREATMENT STRATEGIES FOR HEPATITIS C IN BELGIUM 43 -- 3.1 INTRODUCTION .43 -- 3.2 METHODS 43 -- 3.2.1 Design and analytic technique 43 -- 3.2.2 Perspective .44 -- 3.2.3 Time window and discounting 44 -- 3.2.4 Target population .44 -- 3.2.5 Intervention and comparator 45 -- 3.2.6 Model structure and basic assumptions 45 -- 3.2.7 Transition probabilities 48 -- 3.2.8 Performance of non-invasive liver tests 50 -- 3.2.9 Effectiveness of antiviral treatment .52 -- 3.2.10 Disease management, diagnostic tests and treatment costs 53 -- 3.2.11 Utilities 59 -- 3.2.12 Uncertainty 63 -- 3.2.13 Validation of the model 66 -- 3.3 RESULTS 66 -- 3.3.1 Cost-effectiveness analysis.66 -- 3.3.2 Budget impact analysis .72 -- 4 DISCUSSION AND CONCLUSION 80 -- APPPENDICES 83 -- APPENDIX 1. SCENARIO ANALYSES .83 -- APPENDIX 1.1. KCE REPORTS 157 ANTIVIRAL TREATMENT - ANNUAL TRANSITION PROBABILITIES BETWEEN FIBROSIS STAGES103 83 -- APPENDIX 1.2. TABLES OF THE SCENARIO ANALYSES FOR THE COST-EFFECTIVENESS ANALYSES 86 -- REFERENCES . 137 Link for e-copy: http://doi.org/10.57598/R276C Format of e-copy: PDF (825 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3943 Economic evaluations of pneumococcal vaccination strategies in adults / Nancy Thiry in Acta Clinica Belgica, 60(2005)6 ([11/02/2005])
[article] Economic evaluations of pneumococcal vaccination strategies in adults : A summary of the results [printed text] / Nancy Thiry, Author ; Philippe Beutels, Author ; Pierre Van Damme, Author . - 2005 . - 338-344.
Languages : Dutch (dut) English (eng) French (fre)
in Acta Clinica Belgica > 60(2005)6 [11/02/2005] . - 338-344
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Adult ; Aged ; Belgium ; Cost-Benefit Analysis ; Economics ; Humans ; Journal Article ; Middle Aged ; Peer Review ; Pneumococcal Infections ; Pneumococcal Vaccines ; prevention and control ; VaccinationAbstract: With the view to re-evaluate the current evidence about the efficiency of adult pneumococcal vaccination, we searched the Medline database to collect recent full economic evaluations on this topic. We included a literature review based on studies published up to June 2001 and 5 other studies published between July 2001 and April 2004. Based on these articles' results, pneumococcal vaccination of the elderly aged between 65 and 75 years is found to be relatively cost-effective for the health care payer. There is also evidence that vaccination of HIV+ patients and of young military personnel may be justifiable on the basis of economic evaluation including direct medical costs only. Conclusions about universal vaccination of younger adults (< 65 years) and of high-risk groups could not be drawn because of controversial results. An accurate assessment of the efficiency of adult pneumococcal vaccination is however hard to achieve given the difficulties in collecting valid input data (e.g. for the incidence and mortality of the disease) and given the remaining uncertainties about the vaccine efficacy for non-invasive disease. Finally, by lack of data, none of the studies estimated the impact of vaccination on antimicrobial resistance. Link for e-copy: http://webpublishing.schaubroeck.be/dmp/printflo/content/8/3/navigatie.aspx Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1769 [article]Economic evaluations of varicella vaccination programmes / Nancy Thiry in Pharmacoeconomics, 21(2003)1 ([01/01/2003])
[article] Economic evaluations of varicella vaccination programmes : a review of the literature [printed text] / Nancy Thiry, Author ; Philippe Beutels, Author ; Pierre Van Damme, Author ; Eddy van Doorslaer, Author . - 2003 . - 13-18.
Languages : English (eng)
in Pharmacoeconomics > 21(2003)1 [01/01/2003] . - 13-18
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Chickenpox ; Chickenpox Vaccine ; Child ; Child, Preschool ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Economics ; Economics, Pharmaceutical ; Great Britain ; Humans ; Immunization Programs ; Journal Article ; Peer Review ; prevention and control ; statistics and numerical data [Subheading]Abstract: Chickenpox infections are generally mild but due to their very high incidence among healthy children they give rise to considerable morbidity and occasional mortality. With the development of a varicella vaccine in the early 1970s and its progressive licensing in many countries, interest in the efficiency of varicella immunisation programmes grew. The objective of this review was to discuss the methodological aspects and results of published economic evaluations of varicella vaccination. From this, we attempted to make recommendations. A computerised search was carried out; 17 full economic evaluations of varicella vaccination were retrieved. The review identified the methodological divergences and similarities between the articles in four areas: study design, epidemiological data, economic data and model characteristics. We assessed to what extent the applied methods conform to general guidelines for the economic evaluation of healthcare interventions and compared the studies' results. The desirability of a universal vaccination programme depends on whose perspective is taken. Despite variability in data and model assumptions, the studies suggest that universal vaccination of infants is attractive to society because large savings occur from averted unproductive days for parents. For the healthcare payer, universal vaccination of infants does not generate savings. Vaccination of susceptible adolescents has been proposed by some authors as a viable alternative; the attractiveness of this is highly dependent on the negative predictive value of anamnestic screening. Targeted vaccination of healthcare workers and immunocompromised individuals appears relatively cost effective. Findings for other target groups are either contradictory or provide insufficient evidence for any unequivocal recommendations to be made. High sensitivity to vaccine price was reported in most studies. This review highlights that some aspects of these studies need to be further improved before final recommendations can be made. First, more transparency, completeness and compliance to general methodological guidelines are required. Second, because of the increasing severity of varicella with age, it is preferable and in some cases essential to use dynamic models for the assessment of universal vaccination strategies. Third, most studies focused on the strategy of vaccinating children only while their results depended heavily on disputable assumptions (regarding vaccine effectiveness and impact on herpes zoster). Since violation of these assumptions could have important adverse public health effects, we suggest pre-adolescent vaccination as a more secure alternative. This option deserves more attention in future analyses Link for e-copy: http://adisonline.com/pharmacoeconomics/toc/2003/21010#1491356273 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2435 [article]Economische evaluatie van antivirale behandeling van chronische hepatitis B in België / Christoph Schwierz / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
Economische evaluatie van antivirale behandeling van chronische hepatitis B in België : Deel 2 [printed text] / Christoph Schwierz, Author ; Nancy Thiry, Author ; Stefaan Van de Sande , Author ; Mohamed Gamil, Author ; Frederik Nevens, Author ; Isabelle Colle, Author ; Yvres Horsmans, Author ; Frank Hulstaert, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - X, 77 p. : ill. ; A4. - (KCE Reports A. Health Technology Assessment (HTA); 157A) .
ISSN : D/2011/10.273/27 : € 0,00
studie n° 2008-11 HTA Chronic hep B
Languages : English (eng) Dutch (nla)
Descriptors: Indexation
2008-11 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis B virus ; Hepatitis B, Chronic ; R157
Classification
WC 536 Human viral hepatitisAbstract: Sinds enkele jaren zijn nieuwe geneesmiddelen beschikbaar voor de behandeling van chronische hepatitis B. De kostprijs van deze behandeling bedraagt zowat 5000 euro per patiënt per jaar. De beleidsmakers vroegen aan het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) na te gaan welke groepen patiënten het meest baat kunnen hebben bij deze behandeling, en tegen welke prijs. Het KCE concludeerde dat het behandelen van een meer gevorderd ziektestadium, in dit geval levercirrose, gepaard gaat met de hoogste gezondheidswinst per gespendeerde euro. De berekeningen door het KCE zijn gebaseerd op een origineel onderzoek naar het ziekteverloop en de ziektekosten in samenwerking met een groot aantal leverspecialisten. Contents note: GLOSSARY 2 -- 1 BACKGROUND AND OBJECTIVES 3 -- 1.1 NATURAL HISTORY AND EPIDEMIOLOGY 3 -- 1.2 TREATMENT 4 -- 1.3 OBJECTIVES AND CONTENT OF THE TWO REPORTS 5 -- 2 METHODS 7 -- 2.1 TARGET POPULATION 7 -- 2.2 MODEL STRUCTURE AND BASIC ASSUMPTIONS 7 -- 2.3 TRANSITION PROBABILITIES 9 -- 2.4 DISEASE MANAGEMENT AND TREATMENT COSTS 12 -- 2.5 UTILITIES 13 -- 2.6 ANTIVIRAL TREATMENT 14 -- 3 RESULTS 16 -- 3.1 MODEL VALIDATION: NATURAL EVOLUTION OF DISEASE WITHIN EUROPEAN -- COHORTS 17 -- 3.2 HEALTH OUTCOMES 18 -- 3.2.1 Life-years gained in the three cohorts 18 -- 3.2.2 Undiscounted life-years gained in DC and HCC 19 -- 3.2.3 Mean tenofovir treatment duration in CHB e+ vs e- cohorts 20 -- 3.3 BASE-CASE COST-UTILITY ANALYSES 20 -- 3.3.1 Overview of the results for the three base-case cohorts 20 -- 3.3.2 CHBe+ non-cirrhotic Europeans 21 -- 3.3.3 CHBe- non-cirrhotic Europeans 23 -- 3.3.4 Patient with compensated liver cirrhosis 25 -- 3.4 SCENARIO AND PROBABILISTIC SENSITIVITY ANALYSES 27 -- 3.4.1 Probabilistic sensitivity analysis 27 -- 3.4.2 ICERs in function of the time horizon 30 -- 3.4.3 Asian cohorts 31 -- 3.4.4 Variations in the discount rates 32 -- 3.5 BUDGET IMPACT 33 -- 4 DISCUSSION AND CONCLUSIONS 34 -- 5 APPENDICES 37 -- 5.1 NATURAL PROGRESSION TO LIVER CIRRHOSIS IN 278 CHRONIC HEPATITIS B -- PATIENTS OF EUROPEAN ORIGIN, THE IMPORTANCE OF AGE AND ELEVATED ALT . 37 -- 5.1.1 Introduction 37 -- 5.1.2 Aim 37 -- 5.1.3 Methods 37 -- 5.1.4 Results 38 -- 5.1.5 Discussion and Conclusion 39 -- 5.2 COMPARISON OF PUBLISHED QUALITY OF LIFE DATA 40 -- 5.2.1 Aims 40 -- 5.2.2 Methods 41 -- 5.2.3 Results 43 -- 5.3 DISEASE MANAGEMENT COSTS 46 -- 5.3.1 Data sources 48 -- 5.3.2 Primary inclusion counts 52 -- 5.3.3 Exclusions and sub grouping for cost study 53 -- 5.3.4 Extrapolations for partial lump sum remunerations 59 -- 5.3.5 Results 66 -- 5.3.6 Discussion 72 -- 6 REFERENCES 74 Link for e-copy: http://doi.org/10.57598/R157A Format of e-copy: PDF (1,3 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2583 Copies(0)
Status No copy Economische evaluatie van meerlaags siliconen schuimverband voor de preventie van doorligwonden in het ziekenhuis / Mattias Neyt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2023)
PermalinkEen Belgische waardenset voor de EQ-5D-5L / Nicolas Bouckaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2021)
PermalinkEen quadrivalent vaccin tegen group B meningokokken / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2014)
PermalinkEffectiviteit en kosten-effectiviteit van behandelingen voor rookstop / Ann Van den Bruel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2004)
PermalinkEfficacité et rentabilité des thérapies du sevrage tabagique / Ann Van den Bruel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2004)
PermalinkÉvaluation économique des pansements en mousse multicouches siliconés pour la prévention des escarres à l'hôpital / Mattias Neyt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2023)
PermalinkEvaluation économique du traitement antiviral de l’hépatite B chronique en Belgique / Christoph Schwierz / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkHome Oxygen Therapy / Alain Van Meerhaeghe / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkHome Oxygen Therapy / Alain Van Meerhaeghe / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkICER 2009 Exposé / KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre fédéral d'expertise des soins de santé / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2009)
Permalink